Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data

M. Campioni (), I. Agirrezabal, R. Hajek, J. Minarik, L. Pour, I. Spicka, S. Gonzalez-McQuire, P. Jandova and V. Maisnar
Additional contact information
M. Campioni: Economic Modeling Center of Excellence, Global Health Economics, Amgen (Europe) GmbH
I. Agirrezabal: Economic Modeling Center of Excellence, Global Health Economics, Amgen (Europe) GmbH
R. Hajek: University of Ostrava
J. Minarik: Palacky University Olomouc
L. Pour: University Hospital Brno and Faculty of Medicine Masaryk Universit
I. Spicka: Charles University in Prague, First Faculty of Medicine and General Teaching Hospital
S. Gonzalez-McQuire: Global Health Economics, Amgen (Europe) GmbH
P. Jandova: Amgen s.r.o
V. Maisnar: Charles University in Prague, First Faculty of Medicine and General Teaching Hospital

The European Journal of Health Economics, 2020, vol. 21, issue 2, No 6, 219-233

Abstract: Abstract Objective To predict the real-world (RW) cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in relapsed multiple myeloma (MM) patients after one to three prior therapies. Methods A partitioned survival model that included three health states (progression-free, progressed disease and death) was built. Progression-free survival (PFS), overall survival (OS) and time to discontinuation (TTD) data for the Rd arm were derived using the Registry of Monoclonal Gammopathies in the Czech Republic; the relative treatment effects of KRd versus Rd were estimated from the phase 3, randomised, ASPIRE trial, and were used to predict PFS, OS and TTD for KRd. The model was developed from the payer perspective and included drug costs, administration costs, monitoring costs, palliative care costs and adverse-event related costs collected from Czech sources. Results The base case incremental cost effectiveness ratio for KRd compared with Rd was €73,156 per quality-adjusted life year (QALY) gained. Patients on KRd incurred costs of €117,534 over their lifetime compared with €53,165 for patients on Rd. The QALYs gained were 2.63 and 1.75 for patients on KRd and Rd, respectively. Conclusions Combining the strengths of randomised controlled trials and observational databases in cost-effectiveness models can generate policy-relevant results to allow well-informed decision-making. The current model showed that KRd is likely to be cost-effective versus Rd in the RW and, therefore, the reimbursement of KRd represents an efficient allocation of resources within the healthcare system.

Keywords: Carfilzomib; Multiple myeloma; Cost-effectiveness; Real world; ASPIRE; Registry of Monoclonal Gammopathies (search for similar items in EconPapers)
JEL-codes: I19 (search for similar items in EconPapers)
Date: 2020
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s10198-019-01122-6 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:eujhec:v:21:y:2020:i:2:d:10.1007_s10198-019-01122-6

Ordering information: This journal article can be ordered from
http://www.springer. ... cs/journal/10198/PS2

DOI: 10.1007/s10198-019-01122-6

Access Statistics for this article

The European Journal of Health Economics is currently edited by J.-M.G.v.d. Schulenburg

More articles in The European Journal of Health Economics from Springer, Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ) Contact information at EDIRC.
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().